GRFS saw its Momentum Indicator move above the 0 level on December 13, 2024. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned positive. In of the 76 cases, the stock moved higher in the following days. The odds of a move higher are at .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where GRFS's RSI Oscillator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for GRFS just turned positive on December 16, 2024. Looking at past instances where GRFS's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GRFS advanced for three days, in of 276 cases, the price rose further within the following month. The odds of a continued upward trend are .
GRFS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
GRFS moved below its 50-day moving average on November 19, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GRFS crossed bearishly below the 50-day moving average on November 27, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GRFS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for GRFS entered a downward trend on December 11, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.716) is normal, around the industry mean (5.632). P/E Ratio (68.679) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.266) is also within normal values, averaging (3.004). Dividend Yield (0.045) settles around the average of (0.164) among similar stocks. GRFS's P/S Ratio (0.637) is slightly lower than the industry average of (3.643).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GRFS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GRFS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock worse than average.
a manufacturer of plasma-derived biological medicines
Industry PharmaceuticalsMajor
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
ARCM | 100.50 | N/A | N/A |
Arrow Reserve Capital Management ETF | |||
XMAR | 36.21 | -0.01 | -0.03% |
FT Vest U.S. Eq Enh & ModBufETF-Mar | |||
PZA | 23.82 | -0.12 | -0.50% |
Invesco National AMT-Free Muni Bd ETF | |||
LITP | 6.98 | -0.10 | -1.41% |
Sprott Lithium Miners ETF | |||
URTY | 57.36 | -2.07 | -3.48% |
ProShares UltraPro Russell2000 |
A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.
Ticker / NAME | Correlation To GRFS | 1D Price Change % | ||
---|---|---|---|---|
GRFS | 100% | +5.64% | ||
GIKLY - GRFS | 68% Closely correlated | +2.19% | ||
GIFOF - GRFS | 37% Loosely correlated | N/A | ||
PFE - GRFS | 28% Poorly correlated | +4.67% | ||
GIFLF - GRFS | 23% Poorly correlated | N/A | ||
AMGN - GRFS | 21% Poorly correlated | -0.21% | ||
More |